These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36448735)

  • 1. Fingerprick blood samples to measure serum natalizumab concentrations.
    Toorop AA; Steenhuis M; Loeff FC; Weijers SS; Killestein J; Rispens T; Kempen ZLV
    Mult Scler; 2023 Mar; 29(3):457-460. PubMed ID: 36448735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration.
    Gelissen LMY; Loveless S; Toorop AA; Howlett J; Loeff FC; Rispens T; Killestein J; Tallantyre EC; van Kempen ZLE
    Mult Scler Relat Disord; 2024 Oct; 90():105796. PubMed ID: 39096666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trial.
    Toorop AA; Wessels MHJ; Gelissen LMY; Hoitsma E; Zeinstra EMPE; van Rooij LC; van Munster CEP; Vennegoor A; Mostert JP; Wokke BHA; Kalkers NF; Hoogervorst ELJ; van Eijk JJJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige LGF; Kloosterziel ME; Arnoldus EPJ; van Dijk GW; Bouvy WH; Strijbis EMM; van Oosten BW; de Jong BA; Lissenberg-Witte BI; Rispens T; Uitdehaag BMJ; Killestein J; van Kempen ZLE
    J Neurol Sci; 2024 Jul; 462():123102. PubMed ID: 38925067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis.
    Toorop AA; van Kempen ZLE; Steenhuis M; Nielsen J; Sinnige LGF; van Dijk G; Roosendaal CM; Arnoldus EPJ; Hoitsma E; Lissenberg-Witte BI; de Jong BA; Oosten BWV; Strijbis EMM; Uitdehaag BMJ; Rispens T; Killestein J;
    J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):482-486. PubMed ID: 36639226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis.
    Toorop AA; Rispens T; Strijbis EM; van Oosten BW; de Jong BA; Uitdehaag BM; Killestein J; van Kempen ZL
    Mult Scler; 2022 Feb; 28(2):323-326. PubMed ID: 34931887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T; Fox EJ; Lucas N; Muralidharan KK; Mikol D
    J Clin Pharmacol; 2016 Oct; 56(10):1254-62. PubMed ID: 26835603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Toorop AA; van Lierop ZY; Gelissen LM; Hoitsma E; Zeinstra EM; van Rooij LC; van Munster CE; Vennegoor A; Mostert JP; Wokke BH; Kalkers NF; Hoogervorst EL; van Eijk JJ; Roosendaal CM; Kragt JJ; Eurelings M; van Genugten J; Nielsen J; Sinnige L; Kloosterziel ME; Arnoldus EP; van Dijk GW; Bouvy WH; Wessels MH; Boonkamp L; Strijbis EM; van Oosten BW; De Jong BA; Lissenberg-Witte BI; Barkhof F; Moraal B; Teunissen CE; Rispens T; Uitdehaag BM; Killestein J; van Kempen ZL
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):392-400. PubMed ID: 37963723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
    Koch M
    J Neurol Neurosurg Psychiatry; 2024 Apr; 95(5):391. PubMed ID: 37963724
    [No Abstract]   [Full Text] [Related]  

  • 9. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.
    Moccia M; Loperto I; Santoni L; Masera S; Affinito G; Carotenuto A; Lanzillo R; Triassi M; Morra VB; Palladino R
    Neurodegener Dis Manag; 2022 Jun; 12(3):109-116. PubMed ID: 35446149
    [No Abstract]   [Full Text] [Related]  

  • 10. Intravenous or subcutaneous natalizumab in patients with relapsing-remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study.
    Filippi M; Grimaldi L; Conte A; Totaro R; Valente MR; Malucchi S; Granella F; Cordioli C; Brescia Morra V; Zanetta C; Perini D; Santoni L;
    J Neurol; 2024 Jan; 271(1):340-354. PubMed ID: 37715789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
    Shirani A; Stüve O
    J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploring the effects of extended interval dosing of natalizumab and drug concentrations on brain atrophy in multiple sclerosis.
    Toorop AA; Noteboom S; Steenwijk MD; Gravendeel JW; Jasperse B; Barkhof F; Strijbis EM; Rispens T; Schoonheim MM; van Kempen ZL; Killestein J
    Mult Scler; 2024 Feb; 30(2):266-271. PubMed ID: 38235514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
    Johnsson M; Farman HH; Blennow K; Zetterberg H; Malmeström C; Axelsson M; Lycke J
    Mult Scler; 2022 Nov; 28(13):2070-2080. PubMed ID: 35856574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.
    van Kempen ZLE; Hoogervorst ELJ; Wattjes MP; Kalkers NF; Mostert JP; Lissenberg-Witte BI; de Vries A; Ten Brinke A; van Oosten BW; Barkhof F; Teunissen CE; Uitdehaag BMJ; Rispens T; Killestein J
    Neurology; 2020 Aug; 95(6):e745-e754. PubMed ID: 32690785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Smirnakis K; Xiao S; Kong G; Kuhelj R; Campbell N;
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended interval dosing of natalizumab: More evidence in support.
    Toljan K; Conway DS
    Neurotherapeutics; 2024 Apr; 21(3):e00351. PubMed ID: 38531713
    [No Abstract]   [Full Text] [Related]  

  • 17. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    van Kempen ZL; Leurs CE; Witte BI; de Vries A; Wattjes MP; Rispens T; Killestein J
    Mult Scler; 2018 May; 24(6):805-810. PubMed ID: 28485678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On a 5-year-old girl with multiple sclerosis treated with natalizumab.
    Sotgiu S; Nieddu A; Pruna D; Madrau A; Zarbo IR; Carta A
    Neurol Sci; 2023 Aug; 44(8):2963-2965. PubMed ID: 36991239
    [No Abstract]   [Full Text] [Related]  

  • 19. No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.
    Ryerson LZ; Naismith RT; Krupp LB; Charvet LE; Liao S; Fisher E; de Moor C; Williams JR; Campbell N
    Mult Scler Relat Disord; 2022 Feb; 58():103480. PubMed ID: 35051898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natalizumab extended-interval dosing in a real-life setting.
    Jeantin L; Boudot de la Motte M; Deschamps R; Gueguen A; Gout O; Lecler A; Papeix C; Bensa C
    J Neurol Sci; 2023 Jul; 450():120689. PubMed ID: 37210938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.